Technology Overview

Nucleic acid therapeutics are considered a next-generation drug platform with potential in cancer and rare disease treatment. Domestic demand for short-chain oligonucleotides largely relies on overseas sourcing or outsourcing. ITRI has developed an automated short-chain oligonucleotide synthesis system with production capacity from milligrams to hundreds of grams, supporting process development and scale-up, providing a one-stop solution from R&D to manufacturing.

Technical Superiority

1.Equipped with high-sensitivity real-time reaction monitoring, reducing up to 50% of reagent use and shortening reaction time by over 40% compared to commercial synthesizers, significantly improving synthesis efficiency.

2.Optimized synthesis column design:

3D-printed column flow structure reduces variability from manual packing, improving reaction uniformity.Crude product purity reaches over 85%, outperforming commercial synthesizers.

3.Reusable column surface modification technology:

Overcomes the single-use limitation of conventional solid supports.Reduces solvent consumption, aligning with green manufacturing principles.

Application

1. The first domestically developed nucleic acid synthesizer, featuring high-sensitivity real-time reaction monitoring for precise process control, and proprietary 3D-printed columns that are reusable for multiple cycles, combining performance with cost efficiency.

2. Proven to reduce reagent consumption and shorten reaction times, enabling clients to produce high-quality short-chain oligonucleotides at lower cost and higher efficiency.